兩連板融捷健康(300247.SZ)：中盛溯源未取得國家衞健委等有權部門對幹細胞相關臨牀試驗的批准
格隆匯3月12日丨融捷健康(300247.SZ)公佈，公司股票於連續兩個交易日漲停。
2020年3月5日，公司控股股東融捷投資控股集團有限公司從金道明一致行動人金浩處通過證券交易所大宗交易方式購買了418萬股公司股票，佔公司總股本0.5%，尚未達到深交所規定的披露時點，後續進展若達到相關信息披露標準，公司將及時履行信息披露義務。
2019年，公司的子公司安徽樂金環境科技有限公司家用淨化器、電子口罩(便攜式空氣淨化器)、車載淨化器產品收入預計分別佔公司總收入的4.0135%、0.0015%、0.0004%,對公司經營業績不構成重大影響。
公司投資安徽影聯雲享醫療科技有限公司(“影聯雲享”)人民幣1000萬元，佔影聯雲享股權比例為15%。影聯雲享2019年1-9月累計實現淨利潤為-615.4萬元，對公司的財務和經營業績沒有影響，截止到2019年9月30日，在公司賬面上體現的公允價值為1000萬元，若後期影聯雲享持續虧損、現金流明顯惡化，可持續發展受到威脅，或新一輪融資時估值低於公司投資時的估值時，可能會對公司產生投資減值風險。
安徽中盛溯源生物科技有限公司(“中盛溯源”)與此次疫情無直接相關，未取得國家衞生健康委員會等有權部門對幹細胞相關臨牀試驗的批准；目前尚未取得臨牀實驗批號，故無成功案例。公司投資中盛溯源人民幣8250萬元(其中已支付5500萬元)，佔中盛溯源股權比例為15%。中盛溯源2019年1-9月累計實現淨利潤為-711.05萬元，對公司的財務和經營業績沒有影響，截止到2019年9月30日，在公司賬面上體現的公允價值為5500萬元，若後期中盛溯源功能細胞新藥研發進度和臨牀轉化進度不及預期，或新一輪融資時估值低於公司投資時的估值，或現金流明顯惡化，可持續發展受到威脅時，可能會對公司產生投資減值風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
